Krystal Biotech (NASDAQ:KRYS) Stock Rating Reaffirmed by HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $200.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 23.43% from the company’s previous close.

KRYS has been the topic of a number of other reports. Stifel Nicolaus reissued a “buy” rating and set a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Citigroup upped their price objective on Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, Guggenheim upped their price objective on Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and a consensus target price of $171.00.

Krystal Biotech Trading Up 3.0 %

KRYS stock opened at $162.04 on Monday. The firm has a market capitalization of $4.62 billion, a PE ratio of 2,025.75 and a beta of 0.85. Krystal Biotech has a 1-year low of $82.09 and a 1-year high of $189.97. The business’s 50 day simple moving average is $161.64 and its 200 day simple moving average is $130.95.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The business had revenue of $42.14 million for the quarter, compared to analyst estimates of $27.43 million. During the same period in the previous year, the firm posted ($1.25) earnings per share. As a group, sell-side analysts predict that Krystal Biotech will post 1.89 EPS for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the sale, the chief accounting officer now owns 12,936 shares of the company’s stock, valued at $2,145,823.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the sale, the chief accounting officer now owns 12,936 shares in the company, valued at $2,145,823.68. The disclosure for this sale can be found here. Insiders sold a total of 38,087 shares of company stock worth $6,210,591 in the last ninety days. 14.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds have recently made changes to their positions in the stock. TimesSquare Capital Management LLC bought a new stake in Krystal Biotech during the third quarter worth about $14,272,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Krystal Biotech by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 179,780 shares of the company’s stock worth $20,854,000 after acquiring an additional 17,614 shares during the period. Vanguard Group Inc. grew its holdings in shares of Krystal Biotech by 40.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after acquiring an additional 693,852 shares during the period. Trexquant Investment LP grew its holdings in shares of Krystal Biotech by 8.8% during the 3rd quarter. Trexquant Investment LP now owns 8,113 shares of the company’s stock worth $941,000 after acquiring an additional 657 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Krystal Biotech by 2.0% during the 3rd quarter. Northern Trust Corp now owns 213,263 shares of the company’s stock worth $24,739,000 after acquiring an additional 4,129 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).